Finanzen von Estrella Immunopharma Inc (ESLA)ESLAEstrella Immunopharma Inc

In the context of the broader market, ESLA competes directly with industry leaders such as QNTM and MRKR. With a market capitalization of $42.85M, it holds a leading position in the sector. When comparing efficiency, ESLA's gross margin of N/A stands against QNTM's N/A and MRKR's N/A. Such benchmarking helps identify whether Estrella Immunopharma Inc is trading at a premium or discount relative to its financial performance.

Estrella Immunopharma has reported consistent losses, with a net income of -2,302,339 USD in Q2 2026 and an EPS of -0.05. The company has a current ratio of 0.20, indicating liquidity issues.